Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13621106 | 0.74 | GAA (0.67) | SMN1; SMN2KDM4ETSHRMAPK1MEN1 | |
| SCHEMBL4964666 | 0.74 | KMT2A (0.67) | SMN1; SMN2KDM4ETSHRHPGDMAPK1 | |
| SCHEMBL10353314 | 0.72 | TSHR (0.67) | SMN1; SMN2KDM4ETSHRHPGDMAPK1 | |
| SCHEMBL8321173 | 0.70 | TSHR (0.70) | SMN1; SMN2KDM4ETSHRHPGDMAPK1 | |
| SCHEMBL10353331 | 0.70 | TSHR (0.70) | SMN1; SMN2KDM4ETSHRHPGDMAPK1 | |
| SCHEMBL29393091 | 0.70 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4EHPGDMEN1GAA | |
| SCHEMBL48805 | 0.70 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4EHPGDMEN1GAA | |
| SCHEMBL21065524 | 0.70 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4EMEN1GAAKMT2A | |
| SCHEMBL30522589 | 0.70 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMEN1GAAKMT2A | |
| SCHEMBL18415475 | 0.70 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885KDM4E 3873/4885TSHR 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.